Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1026061 | 0.98 | TAAR1 (0.61) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL14614553 | 0.93 | TAAR1 (0.57) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL10156581 | 0.89 | TAAR1 (0.76) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL7031436 | 0.86 | MEN1 (0.63) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL30229979 | 0.84 | L3MBTL1 (0.67) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL17919923 | 0.80 | TAAR1 (0.64) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL3060595 | 0.80 | TAAR1 (0.64) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL3063318 | 0.80 | TAAR1 (0.64) | TAAR1TMEM97SIGMAR1ATMCYP1A2 | |
| SCHEMBL12342297 | 0.80 | CHRM2 (0.54) | TAAR1SIGMAR1CYP1A2CYP2A6MAPT | |
| SCHEMBL23572283 | 0.78 | ALDH1A1 (0.50) | TAAR1CYP1A2CYP2A6MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060362-B2 | Inhibitors of glucose transporters (GLUTs) | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023196986-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | Syncell (Taiwan) Inc. (TW) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023101556-A1 | NOVEL INHIBITORS OF ASPARTATE TRANSCARBAMOYLASE (ATCASE) AND COMPOSITIONS, METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-06-08 | — | — | WO | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3960767-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| EP-3189840-B1 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3154997-B9 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-2953976-B1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| US-6677324-B1 | MIXTURE INCLUDES 7A-(E-AMINOALKYL)-ESTRATRIENE; HORMONE REPLACEMENT THERAPY; MENOPAUSE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| CN-1131235-C | 11 beta-halogen-7 alpha-substituted estratrienes, method for producing pharmaceutical preparations containing said 11 beta-halogen-7 alpha-substituted estratrienes, and use of said substances for producing medicaments | SCHERING AG (DE) | 2003-12-17 | — | — | CN | disclosed |
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| CN-1286693-A | 11 'beta'-halogen-7 'alpha'-substd estratrienes, method for producing pharmaceutical preparations contg. said 11 'beta'-halogen-7 'alpha'-substd estratrienes and use of same for producing medicaments | SCHERING AG (DE) | 2001-03-07 | — | — | CN | disclosed |
| EP-1054676-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-29 | — | — | EP | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999042109-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5006527-A | Antihistamines, antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-09 | — | — | US | disclosed |
| US-3976634-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060362-B2 | Inhibitors of glucose transporters (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | TAAR1 2425/4885TMEM97 1436/4885SIGMAR1 3017/4885 |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | TAAR1 2799/4885TMEM97 1274/4885SIGMAR1 2844/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | TAAR1 3901/4885TMEM97 3347/4885SIGMAR1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.